Primaura Therapeutics today announced its launch with a mission to develop next-generation genomic medicines that precisely restore physiological protein expression.The company’s proprietary platform, BOOST 2.0, focuses on modulating translation through targeted editing of the Kozak sequence, a key regulator of…